| X-linked agammaglobulinemia
Asceniv vs Xembify
Side-by-side clinical, coverage, and cost comparison for x-linked agammaglobulinemia.Deep comparison between: Asceniv vs Xembify with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXembify has a higher rate of injection site reactions vs Asceniv based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xembify but not Asceniv, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asceniv
Xembify
At A Glance
IV infusion
Every 3-4 weeks
IgG replacement therapy
SC injection
Daily to every 2 weeks
Immune globulin replacement
Indications
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Primary immune deficiency disorder
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 800 mg/kg IV every 3 to 4 weeks; start infusion at 0.5 mg/kg/min for the first 15 minutes and increase gradually up to 8 mg/kg/min if tolerated.
Primary immune deficiency disorder, Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency SC infusion only; treatment-naive: 150 mg/kg/day loading dose for 5 consecutive days, then 150 mg/kg/week maintenance starting Day 8; switching from IVIG: begin 1 week after last IVIG, initial weekly dose (g) = prior IVIG dose (g) x 1.37 / number of weeks between IVIG doses; switching from IGSC: administer same weekly dose (g) as prior IGSC; doses may be adjusted for frequent (2-7 times/week) or biweekly administration.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
Adverse Reactions
Most common (>=5%) Headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, nausea
Postmarketing Apnea, ARDS, cyanosis, dyspnea, bronchospasm, cardiac arrest, vascular collapse, hypotension, coma, loss of consciousness, seizures, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis, pancytopenia, leukopenia, pyrexia, rigors, hepatic dysfunction, abdominal pain
Most common (>=5%) Infusion site erythema, infusion site pain, infusion site swelling, infusion site bruising, infusion site nodule, infusion site pruritus, infusion site induration, infusion site scab, infusion site edema, cough, diarrhea
Postmarketing Anaphylactic reaction, hypersensitivity, aseptic meningitis, dizziness, paresthesia, tachycardia, hypotension, dyspnea, chest discomfort, injection site reactions, chills, fatigue, pain, tremor, laryngospasm
Pharmacology
ASCENIV is an intravenous immunoglobulin replacement therapy that provides a broad spectrum of neutralizing IgG antibodies against bacterial and viral pathogens and their toxins; IgG antibodies act as opsonins to increase phagocytosis and elimination of pathogens from the circulation.
XEMBIFY supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins, and contains antibodies capable of interacting with and altering the activity of immune system cells, though the full mechanism is not completely understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asceniv
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Xembify
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Asceniv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xembify
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Asceniv
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Xembify
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$75/fillfill
ADvantage Ig Patient Support Program: AscenivCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Primary Immune Deficiency - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AscenivView full Asceniv profile
XembifyView full Xembify profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.